Latest Ratios: P/E Ratio -2.3x · EV/EBITDA N/A · ROE N/A. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $100M | $41M | $89M | — | — | — | — |
| Enterprise Value | $-170064643 | $-228875800 | $84M | — | — | — | — |
| P/E Ratio → | -2.29 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 110.07 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | — | — | -1094.6% | — | — | — | — |
| ROA | -464.6% | -464.6% | -280.4% | -1192.1% | -1498.1% | -0.9% | -0.0% |
| ROIC | — | — | — | — | — | — | — |
| ROCE | — | — | -747.6% | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -6.82 | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -3.33 | -1.26 | -2.46 | -1.87 | -0.00 |
Net cash position: cash ($270M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.03 | 0.03 | 1.20 | 0.03 | 0.08 | 0.09 | 0.80 |
| Quick Ratio | 0.03 | 0.03 | 1.20 | 0.03 | 0.08 | 0.09 | 0.80 |
| Cash Ratio | 22.94 | 22.94 | 1.20 | 0.00 | 0.03 | 0.02 | 0.59 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 35.0% | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 35.0% | — | — | — | — |
| Shares Outstanding | — | $29M | $21M | $20M | $23M | $23M | $8M |
Clinical trial execution failure
According to current market data, OSTX trades at a TTM P/E of -1.92, reflecting a valuation driven entirely by clinical-stage optionality rather than earnings, as the company remains pre-revenue and reliant on external capital to sustain its ongoing research and development activities for the OST-HER2 program.
The absence of meaningful P/S or EV/EBITDA multiples underscores that traditional valuation metrics are currently inapplicable to the firm's business model. Investors appear to be pricing the company based on the potential of its immunotherapy platform, though the lack of commercial revenue suggests that any valuation premium is highly sensitive to clinical trial readouts rather than fundamental financial performance.
Based on reported financial figures, OSTX has demonstrated a persistent decay in return on invested capital, with ROIC reaching -11.0% in 2026Q1, a trend that highlights the significant capital intensity required to advance its pipeline without the benefit of offsetting commercial revenue streams.
The negative ROIC trend is consistent with a clinical-stage entity where capital is deployed into long-term R&D assets that have yet to generate economic returns. This suggests that until the company achieves a successful clinical milestone or licensing event, the efficiency of its capital allocation will remain structurally constrained by the high costs of pediatric oncology research.
As reported in recent quarterly filings, the company's liquidity position appears severely strained, with a current ratio of 0.05 in 2026Q1, indicating that current assets are insufficient to cover immediate liabilities and leaving the firm highly vulnerable to any disruption in its capital-raising capabilities.
The extremely low current and quick ratios suggest that the firm's ability to meet short-term obligations is entirely dependent on the timing of external financing or milestone payments. This liquidity profile warrants close monitoring, as any delay in clinical progress could rapidly exacerbate the firm's reliance on dilutive capital markets to maintain operations.
The current ratio is frequently misapplied to clinical-stage biotech firms like OSTX, as it obscures the reality that the company's primary 'assets' are intangible clinical trial data rather than liquid working capital, rendering standard liquidity benchmarks largely irrelevant to the firm's actual survival risk.
Analysts should instead focus on the 'burn-to-milestone' ratio, which measures the cash runway relative to the time required to reach the next clinical data readout. Relying on the current ratio ignores the fact that the company's most significant liabilities are often tied to future research commitments rather than immediate trade payables.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OSTX stock.
OS Therapies Incorporated's current P/E ratio is -2.3x. This places it at the 50th percentile of its historical range.
Based on historical data, OS Therapies Incorporated is trading at a P/E of -2.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.